Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Clinical experience with bezafibrate

R Schubotz, J Schneider, L Hausmann

    Artery
    |January 1, 1980
    PubMed
    Summary
    This summary is machine-generated.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Metabolic basis of high density lipoproteins and apolipoprotein A-I increase by HMG-CoA reductase inhibition in healthy subjects and a patient with coronary artery disease.

    Atherosclerosis·1999
    Same author

    [Alcohol, lipid metabolism and coronary heart disease].

    Herz·1996
    Same author

    Multicenter comparison of micronized fenofibrate and simvastatin in patients with primary type IIA or IIB hyperlipoproteinemia.

    Journal of cardiovascular pharmacology·1996
    Same author

    [Oral contraceptive-induced pancreatitis in the hyperchylomicronemia syndrome].

    Deutsche medizinische Wochenschrift (1946)·1995
    Same author

    Influence of somatostatin to biochemical parameters in patients with primary hyperparathyroidism.

    Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association·1995
    Same author

    [Adrenomyeloneuropathy. A frequent cause of Addison's disease].

    Deutsche medizinische Wochenschrift (1946)·1994
    Same journal

    Effect of aspirin on the contractility of aortic smooth muscle and the course of blood pressure development in male spontaneously hypertensive rats.

    Artery·2000
    Same journal

    Aldehyde induced hypertension in rats: prevention by N-acetyl cysteine.

    Artery·2000
    Same journal

    Effects of a nitric oxide synthase inhibitor on pressor response to angiotensin II in conscious rats.

    Artery·2000
    Same journal

    Vascular innervation in atherogenesis.

    Artery·1997
    Same journal

    Leukocyte flow properties, polymorphonuclear membrane fluidity and cytosolic Ca2+ content in subjects with vascular atherosclerotic disease.

    Artery·1997
    Same journal

    Lipoprotein abnormalities in type 2 diabetic patients. Increased distribution of triglycerides (TG) in very low density lipoprotein (VLDL) and decreased apolipoprotein E/VLDL-TG ratio are risk for ischemic heart disease.

    Artery·1997
    See all related articles

    Bezafibrate effectively lowers cholesterol and triglycerides in patients with primary hyperlipoproteinemia types IIa, IIb, and IV. This potent lipid-lowering agent demonstrated significant reductions in lipid levels over a 12-month treatment period.

    Area of Science:

    • Cardiology
    • Pharmacology
    • Metabolic Disorders

    Background:

    • Primary hyperlipoproteinemia encompasses genetic disorders affecting lipid metabolism.
    • Types IIa, IIb, and IV hyperlipoproteinemia are characterized by elevated cholesterol and/or triglycerides.
    • Effective lipid-lowering agents are crucial for managing cardiovascular risk.

    Purpose of the Study:

    • To evaluate the efficacy of bezafibrate in treating primary hyperlipoproteinemia.
    • To assess the lipid-lowering effects of bezafibrate in different types of hyperlipoproteinemia.
    • To determine the safety and effectiveness of bezafibrate over a 12-month period.

    Main Methods:

    • A randomized controlled trial involving 41 patients with primary hyperlipoproteinemia (types IIa, IIb, IV).

    Related Experiment Videos

  • Patients received bezafibrate (450-600 mg daily) for 12 months, with 8-week placebo periods before and after treatment.
  • Lipid profiles (total cholesterol, triglycerides) were monitored throughout the study.

    • Main Results:

    • Bezafibrate significantly reduced total cholesterol by up to 18.7% and triglycerides by up to 34.6% in types IIa and IIb.
    • In type IV, serum triglycerides decreased by up to 48.2% and cholesterol by 12.2%.
    • A subgroup analysis of 16 patients confirmed significant lipid reductions during bezafibrate treatment.

    Conclusions:

    • Bezafibrate is a potent and effective agent for lowering lipid levels in patients with primary hyperlipoproteinemia.
    • The drug demonstrates significant efficacy across different hyperlipoproteinemia phenotypes.
    • Bezafibrate represents a valuable therapeutic option in the management of dyslipidemia.